Early detection of cancer: Immunoassays for plasma tumor markers

Research output: Contribution to journalArticle

Abstract

Background: Plasma tumor biomarkers are widely used clinically for monitoring response to therapy and detecting cancer recurrence. Only a limited number of them, however, have been used effectively for the early detection of cancer. Objective: To review plasma tumor markers used clinically for the early detection of cancer and to provide expert opinion about future directions. Methods: A literature review, as well as the authors' expert opinion, of plasma tumor markers that have been widely accepted for the early detection of cancer. Results: In the US, only prostate-specific antigen, cancer antigen 125 and α-fetoprotein have been clinically used for the early detection of prostate, ovarian and liver cancers, respectively. Both analytical and clinical issues related to the use of these three markers are discussed. Conclusion: Few plasma tumor markers have been used effectively for the early detection of cancer, mainly because of their limited sensitivity and/or specificity. Multiple approaches have been developed to improve the clinical performance of tumor markers for the early detection of cancer. Metrological traceability and antibody specificity are important issues to ensure comparability of immunoassays for the measurement of plasma tumor markers.

Original languageEnglish (US)
Pages (from-to)597-605
Number of pages9
JournalExpert Opinion on Medical Diagnostics
Volume3
Issue number6
DOIs
StatePublished - Nov 2009

Fingerprint

Tumor Biomarkers
Early Detection of Cancer
Immunoassay
Plasmas
Expert Testimony
Antigens
Fetal Proteins
Antibody Specificity
Prostate-Specific Antigen
Liver Neoplasms
Antibodies
Liver
Ovarian Neoplasms
Neoplasms
Prostatic Neoplasms
Recurrence
Sensitivity and Specificity
Monitoring

Keywords

  • Cancer
  • Early detection
  • Plasma
  • Tumor marker

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine(all)
  • Biochemistry, medical
  • Molecular Medicine

Cite this

Early detection of cancer : Immunoassays for plasma tumor markers. / Meany, Danni L.; Sokoll, Lori J; Chan, Daniel Wan-Yui.

In: Expert Opinion on Medical Diagnostics, Vol. 3, No. 6, 11.2009, p. 597-605.

Research output: Contribution to journalArticle

@article{7196057b771b403e8a178de6259c1ab1,
title = "Early detection of cancer: Immunoassays for plasma tumor markers",
abstract = "Background: Plasma tumor biomarkers are widely used clinically for monitoring response to therapy and detecting cancer recurrence. Only a limited number of them, however, have been used effectively for the early detection of cancer. Objective: To review plasma tumor markers used clinically for the early detection of cancer and to provide expert opinion about future directions. Methods: A literature review, as well as the authors' expert opinion, of plasma tumor markers that have been widely accepted for the early detection of cancer. Results: In the US, only prostate-specific antigen, cancer antigen 125 and α-fetoprotein have been clinically used for the early detection of prostate, ovarian and liver cancers, respectively. Both analytical and clinical issues related to the use of these three markers are discussed. Conclusion: Few plasma tumor markers have been used effectively for the early detection of cancer, mainly because of their limited sensitivity and/or specificity. Multiple approaches have been developed to improve the clinical performance of tumor markers for the early detection of cancer. Metrological traceability and antibody specificity are important issues to ensure comparability of immunoassays for the measurement of plasma tumor markers.",
keywords = "Cancer, Early detection, Plasma, Tumor marker",
author = "Meany, {Danni L.} and Sokoll, {Lori J} and Chan, {Daniel Wan-Yui}",
year = "2009",
month = "11",
doi = "10.1517/17530050903266830",
language = "English (US)",
volume = "3",
pages = "597--605",
journal = "Expert Opinion on Medical Diagnostics",
issn = "1753-0059",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Early detection of cancer

T2 - Immunoassays for plasma tumor markers

AU - Meany, Danni L.

AU - Sokoll, Lori J

AU - Chan, Daniel Wan-Yui

PY - 2009/11

Y1 - 2009/11

N2 - Background: Plasma tumor biomarkers are widely used clinically for monitoring response to therapy and detecting cancer recurrence. Only a limited number of them, however, have been used effectively for the early detection of cancer. Objective: To review plasma tumor markers used clinically for the early detection of cancer and to provide expert opinion about future directions. Methods: A literature review, as well as the authors' expert opinion, of plasma tumor markers that have been widely accepted for the early detection of cancer. Results: In the US, only prostate-specific antigen, cancer antigen 125 and α-fetoprotein have been clinically used for the early detection of prostate, ovarian and liver cancers, respectively. Both analytical and clinical issues related to the use of these three markers are discussed. Conclusion: Few plasma tumor markers have been used effectively for the early detection of cancer, mainly because of their limited sensitivity and/or specificity. Multiple approaches have been developed to improve the clinical performance of tumor markers for the early detection of cancer. Metrological traceability and antibody specificity are important issues to ensure comparability of immunoassays for the measurement of plasma tumor markers.

AB - Background: Plasma tumor biomarkers are widely used clinically for monitoring response to therapy and detecting cancer recurrence. Only a limited number of them, however, have been used effectively for the early detection of cancer. Objective: To review plasma tumor markers used clinically for the early detection of cancer and to provide expert opinion about future directions. Methods: A literature review, as well as the authors' expert opinion, of plasma tumor markers that have been widely accepted for the early detection of cancer. Results: In the US, only prostate-specific antigen, cancer antigen 125 and α-fetoprotein have been clinically used for the early detection of prostate, ovarian and liver cancers, respectively. Both analytical and clinical issues related to the use of these three markers are discussed. Conclusion: Few plasma tumor markers have been used effectively for the early detection of cancer, mainly because of their limited sensitivity and/or specificity. Multiple approaches have been developed to improve the clinical performance of tumor markers for the early detection of cancer. Metrological traceability and antibody specificity are important issues to ensure comparability of immunoassays for the measurement of plasma tumor markers.

KW - Cancer

KW - Early detection

KW - Plasma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=77953403407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953403407&partnerID=8YFLogxK

U2 - 10.1517/17530050903266830

DO - 10.1517/17530050903266830

M3 - Article

C2 - 19966928

AN - SCOPUS:77953403407

VL - 3

SP - 597

EP - 605

JO - Expert Opinion on Medical Diagnostics

JF - Expert Opinion on Medical Diagnostics

SN - 1753-0059

IS - 6

ER -